Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that Imuvert consistently protected against alopecia induced by certain chemotherapy drugs in rats, potentially mediated by a monocyte-derived cytokine like interleukin-1.

Anti-PD-L1 immunotherapy can cause hair loss and unexpected hair color change, but treatment can restore hair growth and color.

This study found that treatment with diphenylcyclopropenone led to more than 75% hair regrowth in 33.3% of patients with alopecia totalis or alopecia universalis, despite notable side effects.

Some people have a genetic variation that makes them less effective at breaking down drugs.

This study reports that two elderly Asian men with primary scrotal extramammary Paget disease showed no response to a 4- to 6-month trial of topical imiquimod 5%.

In this study, researchers optimized the soft drug AR antagonist 14-P1 to create candidate 39, which demonstrated effective AR antagonism and safety in a hair-growth mouse model, showing similar efficacy to pyrilutamide but with quicker onset and a lower risk of systemic toxicity.

This review compares DNA-derived biopolymers, PN and PDRN, in dermatology, emphasizing their distinct molecular characteristics and roles, and reports no new clinical results.

This study suggests that cyclosporine may directly affect epithelial cell growth, potentially leading to broader use of its nonimmunosuppressive analogues in treating hyperproliferative epidermal diseases.

This communication discusses previous reports of deadly hematopoietic depression associated with the topical use of demecolcine for skin cancers, highlighting potential hazards relative to colchicine ointment in psoriasis.

In this study, a dual soft drug design strategy improved the AR antagonist candidate 39, showing potent AR antagonism and good safety in a mouse hair-growth model, with similar efficacy to pyrilutamide but faster response.

In this review, the authors report that tacrolimus ointment shows promise for expanding its use to a variety of skin conditions, beyond its current approval for atopic dermatitis, by analyzing clinical experiences of its application for rosacea, seborrheic dermatitis, psoriasis, and other dermatoses.

This systematic review gathered and analyzed data from 56 studies involving 109 patients to assess dupilumab's effects on alopecia areata, examining factors like disease severity, treatment regimens, and clinical outcomes. Results of these analyses are discussed in the accompanying manuscript.

Baricitinib reduces inflammation and mitochondrial damage in skin cells.

This case report observed a unique presentation of microscopic colitis with granulomatous inflammation in a patient whose symptoms resolved with budesonide treatment, suggesting a possible drug reaction, potentially linked to allopurinol.

This study found that a multimodal microemulsion containing minoxidil, diclofenac, and tea tree oil was significantly more effective and stable than minoxidil alone in treating androgenic alopecia over a 32-week period.

This review suggests that oral Janus kinase inhibitors are a promising treatment for alopecia areata in adults, showing significant hair regrowth with fewer side effects than conventional treatments, while PDE-4 inhibitors and biologics show limited efficacy.

This study found that fibromodulin significantly reduces scar formation and boosts scar strength in rodent and porcine models, suggesting potential for FMOD-based therapies in cutaneous wound repair.

This dataset from a systematic review contains extracted data from 56 studies involving 109 patients to assess dupilumab's effects on alopecia areata, detailing study characteristics, patient demographics, treatment regimens, and clinical outcomes.

This study found cell-specific variations in POMC mRNA and peptide expression in murine skin, suggesting that PC1 and PC2 convertases contribute to differential POMC processing.

This study suggests revising PCOS diagnostic criteria to integrate the polymenorrhoea subcategory due to shared metabolic dysfunctions with oligomenorrhoea.

This review discusses AR-modulating agents developed between 2012 and 2018, highlighting challenges with ligand-binding domain antagonists and proposing nonconventional approaches targeting other domains as promising strategies.

This study found that polymeric micelle formulations significantly improved the targeted delivery of adapalene to hair follicles compared to standard Differin® products, which suggests potential advantages in treating hair follicle-related conditions and reducing side effects.

This study observed that Tudor-SN protein may play a significant role in the immune system and that polyamines can influence hair growth in a mouse model.

In this randomized controlled trial, researchers found that after six months of treatment, oral baricitinib was significantly more effective than methotrexate for improving hair regrowth in patients with severe alopecia areata, as measured by the Severity of Alopecia Tool score.

This study is the first to report that apremilast may be effective in treating refractory lichen planopilaris and frontal fibrosing alopecia, though some patients experienced adverse effects leading to discontinuation.

In this case report, an 8-year-old with severe alopecia areata and atopic dermatitis experienced significant hair regrowth and improved dermatitis symptoms after treatment with dupilumab followed by baricitinib, with no major side effects observed.

This study reported a 74% overall response rate for a new combination chemotherapy of mitoxantrone, etoposide, and prednisolone in patients with relapsed or refractory Hodgkin's disease or non-Hodgkin's lymphoma.

This study concluded that 0.05% betamethasone dipropionate cream is more effective than other topical treatments for improving alopecia areata over 12 weeks.

In this study, researchers found that minoxidil sulfate enhances the anti-inflammatory effects of the JAK inhibitor baricitinib in alopecia areata, modulating inflammatory signals and preserving immune privilege features in human hair cells, which suggests potential benefits for combined therapy.